Revenue Update on Zogenix(NASDAQ:ZGNX)

Zogenix(NASDAQ:ZGNX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $2.09M. Analysts estimated a revenue of $5.36M. Earnings per share were $-0.74. Analysts had estimated an EPS of $-0.81.

Zogenix (ZGNX) made into the market gainers list on Wednesdays trading session with the shares advancing 0.20% or 0.02 points. Due to strong positive momentum, the stock ended at $9.89, which is also near the day’s high of $9.94. The stock began the session at $9.86 and the volume stood at 91,325 shares. The 52-week high of the shares is $21.03 and the 52 week low is $7.33. The company has a current market capitalization of $245 M and it has 2,47,90,989 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Dec 18, 2015, Roger Hawley (director) purchased 10,000 shares at $13.74 per share price.Also, On Dec 8, 2015, Renee P Tannenbaum (director) purchased 5,000 shares at $15.40 per share price.

Zogenix Inc. (Zogenix) is a pharmaceutical company which is engaged in development and commercialization of therapies for people with central nervous system (CNS) disorders. The Company focuses on the areas of pain epilepsy and schizophrenia. It is engaged in the development of Relday a product candidate for the treatment of schizophrenia. The Company develops ZX007 an abuse-deterrent tablet formulation of single entity extended-release hydrocodone. The Company commercializes Sumavel DosePro (sumatriptan injection) a needle-free delivery system. Sumavel DosePro offers the administration of sumatriptan for the acute treatment of migraine and cluster headache. The Company sells Sumavel DosePro to wholesale pharmaceutical distributors pharmacies and hospitals.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *